BlackRock
GENB

BlackRock’s Generate Biomedicines GENB Stock Holding History

BlackRock’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28M Buy
+1,659,966
New +$22.6M ﹤0.01% 3044

Other funds holding GENB

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
MFG
Magnus Financial Group New York $1.41B AUM 23.4% 1-Year Est. Return

BlackRock's GENB Position: Q2 2026 in Review

BlackRock opened a new position in Generate Biomedicines (GENB) in Q2 2026: 1,659,966 shares worth $28M. The stake represents ﹤0.01% of the portfolio and ranks #3044 among its holdings.

25 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • BlackRock held 1,659,966 shares of Generate Biomedicines worth $28M as of Q2 2026.
  • Generate Biomedicines was a new BlackRock position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3044 holding.
  • 25 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.